Personal information

Other IDs

Scopus Author ID: 19640879500

Keywords

Apoptosis, Apo2L/TRAIL, death receptors, Receptor-selective variant DR5-B, Tumor Therapy

Countries

Russia

Activities

Collapse all

Employment (2)

Institute of Bioorganic Chemistry: Moscow, RU

(Bioengineering)
Employment
Source: Self-asserted source
Anne Yagolovich

Lomonosov Moscow State University: Moscow, RU

2014-05-27 to present (Faculty of Biology )
Employment
Source: Self-asserted source
Anne Yagolovich

Education and qualifications (2)

Lomonosov Moscow State University: Moscow, RU

2007-09 to 2011-02 | PhD student (Biology)
Qualification
Source: Self-asserted source
Anne Yagolovich

Lomonosov Moscow State University : Moscow, RU

2002-09 to 2007-06 (Biology)
Qualification
Source: Self-asserted source
Anne Yagolovich

Works (19)

Cytokine TRAIL death receptor agonists: design strategies and clinical prospects

Russian Chemical Reviews
2025-02 | Journal article
DOI: 10.59761/RCR5154
Contributors: A. V. Yagolovich; M. E. Gasparian; A. A. Isakova; A. A. Artykov; D. A. Dolgikh; M. P. Kirpichnikov
Source: check_circle
Crossref

Cytotoxicity of curcumin-loaded nanoparticles based on amphiphilic poly-N-vinylpyrrolidone derivatives in 2D and 3D <i>in vitro</i> models of human ovarian adenocarcinoma

Russian Journal of Oncology
2024-12-21 | Journal article
DOI: 10.17816/onco636712
Contributors: Anastasia M. Gileva; Daria I. Kulikova; Ekaterina V. Kukovyakina; Anne V. Yagolovich; Kirill S. Kushnerev; Andrey N. Kuskov; Elena A. Markvicheva
Source: check_circle
Crossref

Correction: Yagolovich et al. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma. Int. J. Mol. Sci. 2022, 23, 12687

International Journal of Molecular Sciences
2024-05-14 | Journal article
DOI: 10.3390/ijms25105334
Contributors: Anne V. Yagolovich; Alina A. Isakova; Artem A. Artykov; Yekaterina V. Vorontsova; Diana V. Mazur; Nadezhda V. Antipova; Marat S. Pavlyukov; Mikhail I. Shakhparonov; Anastasia M. Gileva; Elena A. Markvicheva et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Toxicity Evaluation and Controlled-Release of Curcumin-Loaded Amphiphilic Poly-N-vinylpyrrolidone Nanoparticles: In Vitro and In Vivo Models

Pharmaceutics
2023-12-19 | Journal article
DOI: 10.3390/pharmaceutics16010008
Contributors: Anna L. Luss; Dmitry V. Bagrov; Anne V. Yagolovich; Ekaterina V. Kukovyakina; Irina I. Khan; Vadim S. Pokrovsky; Maria V. Shestovskaya; Marine E. Gasparian; Dmitry A. Dolgikh; Andrey N. Kuskov
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Doxorubicin-Loaded Polyelectrolyte Multilayer Capsules Modified with Antitumor DR5-Specific TRAIL Variant for Targeted Drug Delivery to Tumor Cells

Nanomaterials
2023-02-27 | Journal article
DOI: 10.3390/nano13050902
Contributors: Anastasia Gileva; Daria Trushina; Anne Yagolovich; Marine Gasparian; Leyli Kurbanova; Ivan Smirnov; Sergey Burov; Elena Markvicheva
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Recent Advances in the Development of Nanodelivery Systems Targeting the TRAIL Death Receptor Pathway

Pharmaceutics
2023-02-03 | Journal article
DOI: 10.3390/pharmaceutics15020515
Contributors: Anne V. Yagolovich; Marine E. Gasparian; Dmitry A. Dolgikh
Source: check_circle
Crossref

DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma

International Journal of Molecular Sciences
2022-10-21 | Journal article
DOI: 10.3390/ijms232012687
Contributors: Anne Yagolovich; Alina Isakova; Artem Artykov; Yekaterina Vorontsova; Diana Mazur; Nadezhda Antipova; Marat Pavlyukov; Mikhail Shakhparonov; Anastasia Gileva; Elena Markvicheva et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Application of an Autoinduction Strategy to Optimize the Heterologous Production of an Antitumor Bispecific Fusion Protein Based on the TRAIL Receptor-Selective Mutant Variant in Escherichia coli

Molecular Biotechnology
2022-09-12 | Journal article
DOI: 10.1007/s12033-022-00561-6
Contributors: Alina Isakova; Artem Artykov; Yekaterina Vorontsova; Dmitry Dolgikh; Mikhail Kirpichnikov; Marine Gasparian; Anne Yagolovich
Source: check_circle
Crossref

Optimized Heterologous Expression and Efficient Purification of a New TRAIL-Based Antitumor Fusion Protein SRH–DR5-B with Dual VEGFR2 and DR5 Receptor Specificity

International Journal of Molecular Sciences
2022-05-24 | Journal article
DOI: 10.3390/ijms23115860
Contributors: Anne V. Yagolovich; Artem A. Artykov; Alina A. Isakova; Yekaterina V. Vorontsova; Dmitry A. Dolgikh; Mikhail P. Kirpichnikov; Marine E. Gasparian
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Antitumor Cytokine DR5-B-Conjugated Polymeric Poly(N-vinylpyrrolidone) Nanoparticles with Enhanced Cytotoxicity in Human Colon Carcinoma 3D Cell Spheroids

2021-11-01 | Conference paper
DOI: 10.3390/IOCPS2021-11281
Contributors: Anne Yagolovich; Andrey Kuskov; Pavel Kulikov; Leily Kurbanova; Anastasia Gileva; Elena Markvicheva
Source: check_circle
Crossref

Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL

Frontiers in Cell and Developmental Biology
2021-09-30 | Journal article
DOI: 10.3389/fcell.2021.733688
Part of ISSN: 2296-634X
Contributors: Artem A. Artykov; Anne V. Yagolovich; Dmitry A. Dolgikh; Mikhail P. Kirpichnikov; Daria B. Trushina; Marine E. Gasparian
Source: Self-asserted source
Anne Yagolovich

Amphiphilic Poly(N-vinylpyrrolidone) Nanoparticles Conjugated with DR5-Specific Antitumor Cytokine DR5-B for Targeted Delivery to Cancer Cells

Pharmaceutics
2021-09-07 | Journal article
DOI: 10.3390/pharmaceutics13091413
Contributors: Anne Yagolovich; Andrey Kuskov; Pavel Kulikov; Leily Kurbanova; Dmitry Bagrov; Artem Artykov; Marine Gasparian; Svetlana Sizova; Vladimir Oleinikov; Anastasia Gileva et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile.

Translational oncology
2020-03-27 | Journal article
DOI: 10.1016/j.tranon.2020.100762
PMID: 32224450
PMC: PMC7110358
Source: Self-asserted source
Anne Yagolovich

A New Efficient Method for Production of Recombinant Antitumor Cytokine TRAIL and Its Receptor-Selective Variant DR5-B

Biochemistry (Moscow)
2019-06 | Journal article
DOI: 10.1134/s0006297919060051
Part of ISSN: 0006-2979
Part of ISSN: 1608-3040
Contributors: A. V. Yagolovich; A. A. Artykov; D. A. Dolgikh; M. P. Kirpichnikov; M. E. Gasparian
Source: Self-asserted source
Anne Yagolovich

The effect of cisplatin on cytotoxicity of anticancer cytokine TRAIL and its receptor-selective mutant variant DR5-B1.

Doklady. Biochemistry and biophysics
2017-11-01 | Journal article
DOI: 10.1134/s1607672917060114
PMID: 29297126
Source: Self-asserted source
Anne Yagolovich

Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.

Biochemistry. Biokhimiia
2015-08-01 | Journal article
DOI: 10.1134/s0006297915080143
PMID: 26547077
Source: Self-asserted source
Anne Yagolovich

Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.

Apoptosis : an international journal on programmed cell death
2009-06-01 | Journal article
DOI: 10.1007/s10495-009-0349-3
PMID: 19412666
Source: Self-asserted source
Anne Yagolovich

Cytoskeleton inhibitors combined with TRAIL induce apoptosis in HeLa carcinoma cells overexpressing antiapoptotic protein Bcl-2.

Biochemistry. Biokhimiia
2008-03-01 | Journal article
DOI: 10.1134/s000629790803019x
PMID: 18393775
Source: Self-asserted source
Anne Yagolovich

Overexpression and refolding of thioredoxin/TRAIL fusion from inclusion bodies and further purification of TRAIL after cleavage by enteropeptidase.

Biotechnology letters
2007-07-04 | Journal article
DOI: 10.1007/s10529-007-9446-y
PMID: 17609857
Source: Self-asserted source
Anne Yagolovich

Peer review (3 reviews for 3 publications/grants)

Review activity for Chemotherapy. (1)
Review activity for Molecular biotechnology. (1)
Review activity for Molecular pharmaceutics. (1)
How many people are using ORCID?